Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director David Scadden Sells 1,400 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) Director David Scadden sold 1,400 shares of the company's stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $40.00, for a total value of $56,000.00. Following the completion of the sale, the director owned 17,603 shares of the company's stock, valued at $704,120. This trade represents a 7.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agios Pharmaceuticals Trading Up 2.0%

Agios Pharmaceuticals stock traded up $0.80 during mid-day trading on Wednesday, hitting $39.99. The company's stock had a trading volume of 628,785 shares, compared to its average volume of 657,377. The firm has a market capitalization of $2.32 billion, a PE ratio of 3.56 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The stock's fifty day moving average is $33.35 and its two-hundred day moving average is $32.16.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. On average, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AGIO. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Scotiabank dropped their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $58.60.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $39,000. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at $40,000. CWM LLC raised its stake in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 996 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 499 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.